de Munk G A, Parkinson J F, Groeneveld E, Bang N U, Rijken D C
IVVO-TNO Gaubius Laboratory, Leiden, The Netherlands.
Biochem J. 1993 Mar 15;290 ( Pt 3)(Pt 3):655-9. doi: 10.1042/bj2900655.
Thrombomodulin (TM), a membrane proteoglycan on endothelial cells, binds thrombin in a 1:1 complex, accelerates the protein C activation by thrombin, promotes the thrombin inactivation by antithrombin III and inhibits the procoagulant properties of thrombin. The inactivation of single-chain urokinase-type plasminogen activator (scu-PA) by thrombin is accelerated about 70-fold by TM [De Munk, Groeneveld and Rijken (1991) J. Clin. Invest. 88, 1680-1684]. The present study investigates the role of the O-linked glycosaminoglycan moiety of TM in the latter reaction. In the presence of an excess of a fully-glycosylated soluble recombinant human TM mutant (high-Mr rec-TM), 0.11 nM thrombin inactivated 50% of 4.4 nM scu-PA in 45 min at 37 degrees C. In the presence of a soluble recombinant TM mutant lacking the glycosaminoglycans (low-Mr rec-TM), 1.9 nM thrombin was needed to inactivate 50% scu-PA, as compared with 4.7 nM thrombin in the absence of TM. Using the scu-PA inactivation assay the dissociation constant for the thrombin-TM interaction was found to be 0.4 nM for high-Mr rec-TM and 14 nM for low-Mr rec-TM. Treatment of high-Mr rec-TM with chondroitinase ABC to digest the glycosaminoglycans decreased the accelerating effect to the level of low-Mr rec-TM. A similar decrease was observed after treatment of solubilized rabbit TM with chondroitinase ABC. As expected, chondroitinase ABC had no influence on the accelerating effect of low-Mr rec-TM. The free glycosaminoglycans obtained by alkaline treatment of TM or chondroitin sulphate A also accelerated the inactivation of scu-PA by thrombin, but about 1000-fold higher concentrations than with TM were needed to obtain the same acceleration. It is concluded that the major glycosaminoglycan of TM plays a pivotal role in the inactivation of scu-PA by the TM-thrombin complex, both in the formation and in the activity of the complex.
血栓调节蛋白(TM)是内皮细胞上的一种膜蛋白聚糖,以1:1复合物的形式与凝血酶结合,加速凝血酶对蛋白C的激活,促进抗凝血酶III对凝血酶的灭活,并抑制凝血酶的促凝血特性。血栓调节蛋白可使凝血酶对单链尿激酶型纤溶酶原激活剂(scu-PA)的灭活加速约70倍[德蒙克、格罗内维尔德和里肯(1991年)《临床研究杂志》88卷,第1680 - 1684页]。本研究探讨了血栓调节蛋白的O-连接糖胺聚糖部分在后者反应中的作用。在存在过量的完全糖基化可溶性重组人血栓调节蛋白突变体(高Mr重组TM)的情况下,0.11 nM凝血酶在37℃下45分钟内使4.4 nM scu-PA的50%失活。在存在缺乏糖胺聚糖的可溶性重组血栓调节蛋白突变体(低Mr重组TM)的情况下,需要1.9 nM凝血酶才能使50%的scu-PA失活,而在不存在血栓调节蛋白时则需要4.7 nM凝血酶。使用scu-PA失活测定法,发现高Mr重组TM的凝血酶 - 血栓调节蛋白相互作用的解离常数为0.4 nM,低Mr重组TM为14 nM。用软骨素酶ABC处理高Mr重组TM以消化糖胺聚糖,可使加速作用降低至低Mr重组TM的水平。在用软骨素酶ABC处理溶解的兔血栓调节蛋白后也观察到类似的降低。正如预期的那样,软骨素酶ABC对低Mr重组TM的加速作用没有影响。通过对血栓调节蛋白或硫酸软骨素A进行碱性处理获得的游离糖胺聚糖也能加速凝血酶对scu-PA的灭活,但需要比血栓调节蛋白高约一千倍的浓度才能获得相同的加速效果。得出的结论是,血栓调节蛋白的主要糖胺聚糖在血栓调节蛋白 - 凝血酶复合物对scu-PA的灭活中起关键作用,在复合物的形成和活性方面均如此。